Edition:
United Kingdom

People: Aclaris Therapeutics Inc (ACRS.OQ)

ACRS.OQ on NASDAQ Stock Exchange Global Select Market

4.45USD
26 Jun 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$4.45
Open
$4.45
Day's High
$4.51
Day's Low
$4.32
Volume
129,272
Avg. Vol
164,882
52-wk High
$21.31
52-wk Low
$4.27

Shanler, Stuart 

Mr. Stuart D. Shanler M.D. is Chief Scientific Officer since July 2012. Since January 2014, Dr. Shanler has served part-time as a medical and clinical development consultant at Ralexar Therapeutics, Inc., a specialty dermatology company. Between 2011 and 2012, Dr. Shanler served as a consultant to a number of pharmaceutical companies. Dr. Shanler co-invented RHOFADE, a topical drug for the treatment of persistent facial erythema, for, and co-founded and served as Chief Scientific Officer of, Vicept Therapeutics, Inc. from 2009 until its acquisition by Allergan, Inc. in July 2011. Previously, Dr. Shanler was a dermatologic surgeon in private practice. Dr. Shanler is a board-certified dermatologist and received his M.D. degree from Albany Medical College of Union University and received B.S. degrees in Biology and the Biological Basis of Behavior from the University of Pennsylvania.

Basic Compensation

Total Annual Compensation, USD 400,000
Restricted Stock Award, USD 342,395
Long-Term Incentive Plans, USD --
All Other, USD 1,066,040
Fiscal Year Total, USD 1,808,440

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Neal Walker

4,363,390

Frank Ruffo

--

Stuart Shanler

1,808,440

Kamil Ali-Jackson

2,725,200

David Gordon

2,116,180

William Humphries

156,980
As Of  31 Dec 2018